Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor.

Collin MP, Lobell M, Hübsch W, Brohm D, Schirok H, Jautelat R, Lustig K, Bömer U, Vöhringer V, Héroult M, Grünewald S, Hess-Stumpp H.

ChemMedChem. 2018 Mar 6;13(5):437-445. doi: 10.1002/cmdc.201700718. Epub 2018 Feb 16.

PMID:
29451369
2.

Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.

Schneider H, Szabo E, Machado RA, Broggini-Tenzer A, Walter A, Lobell M, Heldmann D, Süssmeier F, Grünewald S, Weller M.

J Neurochem. 2017 Jan;140(1):170-182. doi: 10.1111/jnc.13877. Epub 2016 Dec 12.

3.

Best of both worlds: combining pharma data and state of the art modeling technology to improve in Silico pKa prediction.

Fraczkiewicz R, Lobell M, Göller AH, Krenz U, Schoenneis R, Clark RD, Hillisch A.

J Chem Inf Model. 2015 Feb 23;55(2):389-97. doi: 10.1021/ci500585w. Epub 2014 Dec 16.

PMID:
25514239
4.

CypScore: Quantitative prediction of reactivity toward cytochromes P450 based on semiempirical molecular orbital theory.

Hennemann M, Friedl A, Lobell M, Keldenich J, Hillisch A, Clark T, Göller AH.

ChemMedChem. 2009 Apr;4(4):657-69. doi: 10.1002/cmdc.200800384.

PMID:
19243088
5.

Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.

Schirok H, Kast R, Figueroa-Pérez S, Bennabi S, Gnoth MJ, Feurer A, Heckroth H, Thutewohl M, Paulsen H, Knorr A, Hütter J, Lobell M, Münter K, Geiss V, Ehmke H, Lang D, Radtke M, Mittendorf J, Stasch JP.

ChemMedChem. 2008 Dec;3(12):1893-904. doi: 10.1002/cmdc.200800211.

PMID:
18973168
6.

Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.

Kast R, Schirok H, Figueroa-Pérez S, Mittendorf J, Gnoth MJ, Apeler H, Lenz J, Franz JK, Knorr A, Hütter J, Lobell M, Zimmermann K, Münter K, Augstein KH, Ehmke H, Stasch JP.

Br J Pharmacol. 2007 Dec;152(7):1070-80. Epub 2007 Oct 15.

7.

In silico ADMET traffic lights as a tool for the prioritization of HTS hits.

Lobell M, Hendrix M, Hinzen B, Keldenich J, Meier H, Schmeck C, Schohe-Loop R, Wunberg T, Hillisch A.

ChemMedChem. 2006 Nov;1(11):1229-36.

PMID:
16991174
8.

Creating the environment for a successful community partnership.

Coe K, Wilson C, Eisenberg M, Attakai A, Lobell M.

Cancer. 2006 Oct 15;107(8 Suppl):1980-6.

9.

Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia.

Mahadevan D, DiMento J, Croce KD, Riley C, George B, Fuchs D, Mathews T, Wilson C, Lobell M.

Am J Hematol. 2006 Oct;81(10):779-86.

10.

Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits.

Wunberg T, Hendrix M, Hillisch A, Lobell M, Meier H, Schmeck C, Wild H, Hinzen B.

Drug Discov Today. 2006 Feb;11(3-4):175-80. Review.

PMID:
16533716
12.

Molecular characterization of the principal substrate binding site of the ubiquitous folding catalyst protein disulfide isomerase.

Pirneskoski A, Klappa P, Lobell M, Williamson RA, Byrne L, Alanen HI, Salo KE, Kivirikko KI, Freedman RB, Ruddock LW.

J Biol Chem. 2004 Mar 12;279(11):10374-81. Epub 2003 Dec 18.

13.

A conserved arginine plays a role in the catalytic cycle of the protein disulphide isomerases.

Lappi AK, Lensink MF, Alanen HI, Salo KE, Lobell M, Juffer AH, Ruddock LW.

J Mol Biol. 2004 Jan 2;335(1):283-95.

PMID:
14659757
14.

Correlates of mammogram density in southwestern Native-American women.

Roubidoux MA, Kaur JS, Griffith KA, Sloan J, Wilson C, Novotny P, Lobell M.

Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):552-8.

15.

Recent advances in the prediction of blood-brain partitioning from molecular structure.

Lobell M, Molnár L, Keserü GM.

J Pharm Sci. 2003 Feb;92(2):360-70.

PMID:
12532385
16.

Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.

Clements JM, Beckett RP, Brown A, Catlin G, Lobell M, Palan S, Thomas W, Whittaker M, Wood S, Salama S, Baker PJ, Rodgers HF, Barynin V, Rice DW, Hunter MG.

Antimicrob Agents Chemother. 2001 Feb;45(2):563-70.

17.

Barriers to cancer screening in Mexican-American women.

Lobell M, Bay RC, Rhoads KV, Keske B.

Mayo Clin Proc. 1998 Apr;73(4):301-8.

PMID:
9559032
18.

The breast: in-plane x-ray protection during diagnostic thoracic CT--shielding with bismuth radioprotective garments.

Hopper KD, King SH, Lobell ME, TenHave TR, Weaver JS.

Radiology. 1997 Dec;205(3):853-8.

PMID:
9393547
19.

Homoharringtonine-induced hyperglycemia.

Sylvester RK, Lobell M, Ogden W, Stewart JA.

J Clin Oncol. 1989 Mar;7(3):392-5.

PMID:
2645387
20.

Lymphocyte aggregation in response to adrenergic stimulation.

Hammerschmidt DE, Jeanneret C, Husak M, Lobell M, Jacob HS.

Blood. 1988 May;71(5):1470-4.

PMID:
2896030
21.

Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia.

Yunis JJ, Lobell M, Arnesen MA, Oken MM, Mayer MG, Rydell RE, Brunning RD.

Br J Haematol. 1988 Feb;68(2):189-94.

PMID:
3162379
22.

Excretion of hydroxyurea into milk.

Sylvester RK, Lobell M, Teresi ME, Brundage D, Dubowy R.

Cancer. 1987 Nov 1;60(9):2177-8.

PMID:
3481556
23.

Cytarabine-induced cerebellar syndrome: case report and literature review.

Sylvester RK, Fisher AJ, Lobell M.

Drug Intell Clin Pharm. 1987 Feb;21(2):177-80.

PMID:
3470173
24.

Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes.

Yunis JJ, Rydell RE, Oken MM, Arnesen MA, Mayer MG, Lobell M.

Blood. 1986 Jun;67(6):1721-30.

PMID:
3708158
25.

Ibuprofen-associated pure white-cell aplasia.

Mamus SW, Burton JD, Groat JD, Schulte DA, Lobell M, Zanjani ED.

N Engl J Med. 1986 Mar 6;314(10):624-5. No abstract available.

PMID:
3945248
26.

Clinical manifestations of acute leukemia.

Lobell M.

Minn Med. 1985 May;68(5):357-60. No abstract available.

PMID:
3859746
27.

High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia.

Yunis JJ, Brunning RD, Howe RB, Lobell M.

N Engl J Med. 1984 Sep 27;311(13):812-8.

PMID:
6472383
28.

Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine, and bleomycin.

Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA.

Ther Drug Monit. 1984;6(3):302-5.

PMID:
6209833
29.

Mitogenic response to Toxocara antigen and chemotactic defect in visceral larva migrans.

Caldwell K, Lobell M, Coccia PF.

Am J Dis Child. 1980 Sep;134(9):845-7.

PMID:
6998281
30.

Induction of myeloperoxidase deficiency in granulocytes in lead-intoxicated dogs.

Caldwell KC, Taddeini L, Woodburn RL, Anderson GL, Lobell M.

Blood. 1979 Apr;53(4):588-93.

PMID:
218596
31.

Drug induced hemolytic anemia.

Lobell M, Woodburn R.

Minn Med. 1975 Mar;58(3):239-43. No abstract available.

PMID:
1113723
32.

Primary dissecting aneurysm of the hepatic artery.

Hill DE, Lobell M, Edwards JE.

Arch Intern Med. 1974 Mar;133(3):471-4. No abstract available.

PMID:
4811485
33.
34.

Cesarean section in the case of twins.

POSNER LB, LOBELL MJ, POSNER AC.

Obstet Gynecol. 1961 Sep;18:355-9. No abstract available.

PMID:
13737382

Supplemental Content

Loading ...
Support Center